Teleflex vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Teleflex Incorporated (TFX)

Q3 202623 Jun – 15 Aug 2026

▲2▼2

Teleflex's portfolio reshape brings FDA wins but integration and guidance cuts weigh

FDA approves first freeze-dried plasma product The FDA approved EZPLAZ, the first licensed freeze-dried plasma, a new product for bleeding emergencies. It opens a new market and supports long-term growth, though near-term sales will be small. This is a genuine new regulatory win that lifts the growth story.
New FDA approval is a concrete positive catalyst for future revenue.
Freesolve heart scaffold trial advances Teleflex started a large global trial for its Freesolve resorbable magnesium scaffold and finished another trial early. Positive early data support a future product that could compete in heart stents. This is a long-term pipeline boost, not immediate revenue.
New trial milestone shows pipeline progress that could drive future growth.
2026 revenue growth outlook cut on slow integration Teleflex lowered its 2026 revenue growth forecast to 3.5%-4.5% from 4.5%-5.5%, blaming slower integration of its vascular intervention business. The interventional segment revenue fell 1% in Q2. This directly reduces expected sales and pressures the stock.
Guidance cut is a key negative driver for the stock price.
2026 GAAP earnings guidance cut after weak Q2 Teleflex cut its 2026 GAAP EPS guidance to $2.54-$2.84 after lower Q2 net income and extended integration timelines. While adjusted EPS was raised, the GAAP cut highlights profitability challenges. Investors focus on how the portfolio reshape converts to sustainable earnings.
Earnings guidance cut is a direct negative for investor sentiment and valuation.

July 202623 Jun – 15 Aug 2026

▲2▼2

Teleflex's portfolio reshape brings FDA wins but integration and guidance cuts weigh

FDA approves first freeze-dried plasma product The FDA approved EZPLAZ, the first licensed freeze-dried plasma, a new product for bleeding emergencies. It opens a new market and supports long-term growth, though near-term sales will be small. This is a genuine new regulatory win that lifts the growth story.
New FDA approval is a concrete positive catalyst for future revenue.
Freesolve heart scaffold trial advances Teleflex started a large global trial for its Freesolve resorbable magnesium scaffold and finished another trial early. Positive early data support a future product that could compete in heart stents. This is a long-term pipeline boost, not immediate revenue.
New trial milestone shows pipeline progress that could drive future growth.
2026 revenue growth outlook cut on slow integration Teleflex lowered its 2026 revenue growth forecast to 3.5%-4.5% from 4.5%-5.5%, blaming slower integration of its vascular intervention business. The interventional segment revenue fell 1% in Q2. This directly reduces expected sales and pressures the stock.
Guidance cut is a key negative driver for the stock price.
2026 GAAP earnings guidance cut after weak Q2 Teleflex cut its 2026 GAAP EPS guidance to $2.54-$2.84 after lower Q2 net income and extended integration timelines. While adjusted EPS was raised, the GAAP cut highlights profitability challenges. Investors focus on how the portfolio reshape converts to sustainable earnings.
Earnings guidance cut is a direct negative for investor sentiment and valuation.

Latest23 Jun – 15 Aug 2026

▲2▼2

Teleflex's portfolio reshape brings FDA wins but integration and guidance cuts weigh

FDA approves first freeze-dried plasma product The FDA approved EZPLAZ, the first licensed freeze-dried plasma, a new product for bleeding emergencies. It opens a new market and supports long-term growth, though near-term sales will be small. This is a genuine new regulatory win that lifts the growth story.
New FDA approval is a concrete positive catalyst for future revenue.
Freesolve heart scaffold trial advances Teleflex started a large global trial for its Freesolve resorbable magnesium scaffold and finished another trial early. Positive early data support a future product that could compete in heart stents. This is a long-term pipeline boost, not immediate revenue.
New trial milestone shows pipeline progress that could drive future growth.
2026 revenue growth outlook cut on slow integration Teleflex lowered its 2026 revenue growth forecast to 3.5%-4.5% from 4.5%-5.5%, blaming slower integration of its vascular intervention business. The interventional segment revenue fell 1% in Q2. This directly reduces expected sales and pressures the stock.
Guidance cut is a key negative driver for the stock price.
2026 GAAP earnings guidance cut after weak Q2 Teleflex cut its 2026 GAAP EPS guidance to $2.54-$2.84 after lower Q2 net income and extended integration timelines. While adjusted EPS was raised, the GAAP cut highlights profitability challenges. Investors focus on how the portfolio reshape converts to sustainable earnings.
Earnings guidance cut is a direct negative for investor sentiment and valuation.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.